Items Tagged ‘PARP3’

September 6th, 2016

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

By

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer […]

View full entry

Tags: Breakthrough Therapy Designation, News, Ovarian Cancer, PARP1, PARP2, PARP3, Stage II-IV Ovarian Cancer